# LONGEVERON INC. (LGVN) · Edgar & Edgarette company card

> Longeveron (LGVN) saw revenue fall 49.9% in FY2025 to $1 million, operating margin -1942% against a -3.8% median for pharmaceutical preparations, equity 55.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1721484 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/LGVN) · [JSON](https://www.pops4.com/boards/company/LGVN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | -49.9% |
| Revenue growth per year | -2.1% |
| Operating margin | -1942.2% (prior year -690.7%) |
| Net margin | -1893.6% |
| Operating cash flow | −$19M |
| Capital spending | $245,000 |
| Free cash flow | −$19M |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $10M |
| Total equity | $6M |
| Equity ÷ assets | 55.3% |
| Return on equity | -400.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -55.12 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -1942.2% in FY2025; revenue is hard to predict: its 80% range is ±85%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $1.2M (FY2025). Experience: revenue down 49.9% on the year, down 2.1% a year over 4 years; operating margin -1942.2%, down from -690.7%. Soundness: equity 55.3% of assets, return on equity -400.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $251K and $3.2M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $211K to $3.8M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1942.2% against a -3.8% median; growth -49.9% against 13.7%.

Range logged 2026-10-15, receipt a4f42ea7faf9576e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-03-25 ([filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026034045/0001213900-26-034045-index.htm))
- Item 5.02 Director or officer change: 10, latest 2026-11-05 ([filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026116360/0001213900-26-116360-index.htm))

## Recent filings

- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026119052/0001213900-26-119052-index.htm)
- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1721484/000119312526458450/0001193125-26-458450-index.htm)
- 8-K · filed 2026-11-05 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026116360/0001213900-26-116360-index.htm)
- 8-K · filed 2026-10-26 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026112508/0001213900-26-112508-index.htm)
- 8-K · filed 2026-10-14 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026109411/0001213900-26-109411-index.htm)
- 8-K · filed 2026-09-23 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/0001213900-26-102611-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001721484.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1721484

## Cite

POPS4, Edgar & Edgarette: LONGEVERON INC. (LGVN) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/LGVN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

